The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida
- PMID: 22708003
- PMCID: PMC3366443
The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida
Abstract
Background: Incidence of nonmelanoma skin cancer and actinic keratoses appears to be increasing worldwide due to increasing levels of ultraviolet radiation, lifestyle changes, and an aging population. Because of its demographics and geographic location, the population of South Florida is at risk for high rates of nonmelanoma skin cancer and actinic keratoses.
Objective: To determine the incidence of nonmelanoma skin cancer and actinic keratoses in two populations in South Florida by measuring treatments by dermatologists in health maintenance organization gatekeeper populations.
Methods: The incidence of nonmelanoma skin cancer and actinic keratoses in South Florida was determined by evaluating the number of nonmelanoma skin cancers and actinic keratoses treated by dermatologists (Current Procedural Terminology [CPT] Code Analysis) in two health maintenance organization populations; "commercial" (age 0-65, mean 27) and Medicare (age 65+, mean 68) in the calendar year 1996.
Results: The incidence of treatment of nonmelanoma skin cancer was 466.5 per 100,000 people per year in the "commercial" (age 0 to 65) population and 10,689.8 per 100,000 people per year in the Medicare age population. The incidence of treated actinic keratoses was 4,464.6 per 100,000 people per year and 110,450.3 in each population respectively.
Conclusion: The studied populations in South Florida appear to have some of the highest incidence rates of nonmelanoma skin cancer in the world and extremely high rates of actinic keratoses. The findings suggest that there is an epidemic of nonmelanoma skin cancer in the South Florida community, which has significant implications for the future medical needs of both "commercial" and Medicare-age populations.
Conflict of interest statement
Figures
Similar articles
-
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29. J Natl Cancer Inst. 2010. PMID: 21115882 Free PMC article. Clinical Trial.
-
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.N Engl J Med. 2015 Oct 22;373(17):1618-26. doi: 10.1056/NEJMoa1506197. N Engl J Med. 2015. PMID: 26488693 Clinical Trial.
-
Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions.Dermatol Surg. 1998 Sep;24(9):981-5. Dermatol Surg. 1998. PMID: 9754086
-
Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.J Cutan Med Surg. 2013 May-Jun;17(3):173-9. doi: 10.2310/7750.2012.12050. J Cutan Med Surg. 2013. PMID: 23673300 Review.
-
Actinic keratosis. Current treatment options.Am J Clin Dermatol. 2000 May-Jun;1(3):167-79. doi: 10.2165/00128071-200001030-00004. Am J Clin Dermatol. 2000. PMID: 11702298 Review.
Cited by
-
Testing Multi-Theory Model (MTM) in Explaining Sunscreen Use among Florida Residents: An Integrative Approach for Sun Protection.Healthcare (Basel). 2021 Oct 10;9(10):1343. doi: 10.3390/healthcare9101343. Healthcare (Basel). 2021. PMID: 34683023 Free PMC article.
-
Safety and Efficacy of Oral Polypodium leucotomos Extract in Healthy Adult Subjects.J Clin Aesthet Dermatol. 2015 Feb;8(2):19-23. J Clin Aesthet Dermatol. 2015. PMID: 25741399 Free PMC article.
-
Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials.Sci Rep. 2022 Apr 7;12(1):5884. doi: 10.1038/s41598-022-09722-8. Sci Rep. 2022. PMID: 35393452 Free PMC article.
-
Primary care review of actinic keratosis and its therapeutic options: a global perspective.Dermatol Ther (Heidelb). 2015 Mar;5(1):19-35. doi: 10.1007/s13555-015-0070-9. Epub 2015 Feb 3. Dermatol Ther (Heidelb). 2015. PMID: 25647448 Free PMC article.
-
The Future of Contract Research Organizations in Dermatology and Aesthetic Research.J Clin Aesthet Dermatol. 2022 Dec;15(12 Suppl 1):S28-S31. J Clin Aesthet Dermatol. 2022. PMID: 36588785 Free PMC article. Review.
References
-
- American Cancer Society. Cancer Facts and Figures 2011. [October 3, 2011]. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/can...
-
- Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–287. - PubMed
-
- Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA Cancer J Clin. 1990;40(1):9–26. - PubMed
-
- Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989;262(15):2097–2100. - PubMed
-
- Kaldor J, Shuff D, Young B, Dwyer T, Wang YG. Nonmelanoma skin cancer: ten years of cancer-registry-based surveillance. Int J Cancer. 1993;53(6):886–891. - PubMed
LinkOut - more resources
Full Text Sources